196 related articles for article (PubMed ID: 15870873)
1. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
2. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
4. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).
Ragnhammar P; Magnusson I; Masucci G; Mellstedt H
Med Oncol Tumor Pharmacother; 1993; 10(1-2):61-70. PubMed ID: 8258997
[TBL] [Abstract][Full Text] [Related]
6. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
[TBL] [Abstract][Full Text] [Related]
8. MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.
Frödin JE; Fagerberg J; Hjelm Skog AL; Liljefors M; Ragnhammar P; Mellstedt H
Hybrid Hybridomics; 2002 Apr; 21(2):99-101. PubMed ID: 12031098
[TBL] [Abstract][Full Text] [Related]
9. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
[TBL] [Abstract][Full Text] [Related]
12. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.
Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL
J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.
Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CG; Steinitz M; Fagerberg J; Mellstedt H
Clin Cancer Res; 2004 Aug; 10(16):5391-402. PubMed ID: 15328177
[TBL] [Abstract][Full Text] [Related]
14. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
Fukuda M; Horibe K; Furukawa K
Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
[TBL] [Abstract][Full Text] [Related]
16. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).
Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Ljungberg A; Hjelm AL; Fagerberg J; Lindemalm C; Osterborg A; Wersäll P
Acta Oncol; 1991; 30(8):923-31. PubMed ID: 1777244
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
Flieger D; Hoff AS; Sauerbruch T; Schmidt-Wolf IG
Clin Exp Immunol; 2001 Jan; 123(1):9-14. PubMed ID: 11167991
[TBL] [Abstract][Full Text] [Related]
19. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
20. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
